- Home
- MLTX vs SPRY Comparison
MLTX vs SPRY Comparison
Compare MLTX & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLTX | SPRY |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MLTX | SPRY |
|---|---|---|
| Price | $15.69 | $9.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | $22.22 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.7M |
| Earning Date | 02-25-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $142,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $126.72 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5459.66 |
| 52 Week Low | $5.95 | $6.66 |
| 52 Week High | $62.75 | $18.90 |
Technical Indicators
Market Signals| Indicator | MLTX | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 51.98 | 41.45 |
| Support Level | $14.47 | $9.60 |
| Resistance Level | $16.69 | $10.74 |
| Average True Range (ATR) | 0.88 | 0.55 |
| MACD | -0.17 | -0.10 |
| Stochastic Oscillator | 49.79 | 3.88 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.